


# Prince Edward Island Guidelines for the Management and Control of COVID-19



Updated: March 24, 2020

# COVID-19

# **Table of Contents**

Case Definition (1)	3
Person Under Investigation (PUI)	3
Confirmed Case	3
Probable Case	3
Prince Edward Island Exposure Criteria	4
Reporting Requirements	5
Etiology (4)	5
Clinical Presentation	5
Diagnosis	6
Epidemiology	6
Occurrence	6
Control (Appendix B)	7
Person Under Investigation (PUI)	7
Management of a Case/PUI	7
Treatment of a Case	7
Management of Contacts	7
Self-Isolating in the Home Setting	7
Testing	8
Infection Prevention and Control in the Community	9
Infection Prevention and Control in the Healthcare Facility	9
Early Recognition and Source Control	9
Application of Routine Practices and Additional Precautions	10
Infection Prevention and Control Guidelines	10
References	12
Appendix A: Novel Coronavirus (COVID-19) Testing	13
Appendix B- Public Health Follow-up	14
Appendix C - Case Report form	20
Appendix D: Symptom Diary for Self- Isolation	20
March 24, 2020	1

# Case Definition (1)

# **Person Under Investigation (PUI)**

• A person with fever and/or cough who meets the exposure criteria and for whom a laboratory test for COVID-19<sup>1</sup> has been or is expected to be requested.

Note: There is limited evidence on the likelihood of COVID-19 presenting as a co-infection with other pathogens. At this time, the identification of one causative agent should not exclude COVID-19 where the index of suspicion<sup>2</sup> may be high.

# **Confirmed Case**

A person with laboratory confirmation of infection with the virus that causes COVID-19 is performed at a reference laboratory (NML or a provincial public health laboratory), and consists of positive nucleic acid amplification tests<sup>3</sup> (NAAT) on at least two specific genome targets or a single positive target with nucleic acid sequencing.

Positive laboratory tests at a non-reference laboratory require additional testing at a reference laboratory for confirmation.

# **Probable Case**

A person:

- with fever (over 38.0 degrees Celsius) and/or new onset of (or exacerbation of chronic) cough
   AND
- who meets the COVID-19 exposure criteria
- in whom laboratory diagnosis of COVID-19 is
  - o inconclusive<sup>4</sup>,
  - o negative (if specimen quality or timing is suspect), or
  - o positive but not confirmed by the National Microbiology Laboratory (NML) or provincial public health laboratory by nucleic acid amplification tests (NAAT)

tests are evolving for this emerging pathogen and laboratory testing recommendations will change accordingly as new assays are developed and validated.

March 24, 2020 3

\_

<sup>&</sup>lt;sup>1</sup> COVID-19 consists of the CO in coronavirus, VI in virus and D for disease; 19 stands for the year 2019 (formally 2019-nCoV)

<sup>&</sup>lt;sup>2</sup> Other exposure scenarios not specifically mentioned here may arise and may be considered at jurisdictional discretion (e.g. history of being a patient in the same ward or facility during a nosocomial outbreak of COVID-19).
<sup>3</sup> Nucleic acid amplification tests must be validated for detection of the virus that causes COVID-19. Laboratory

<sup>&</sup>lt;sup>4</sup> Inconclusive is defined as a positive test on a single real-time PCR target or a positive test with an assay that has limited performance data available.

# **Prince Edward Island Exposure Criteria**

In the 14 days<sup>5</sup> before onset of illness, a person who:

- Traveled outside Prince Edward Island (PEI) OR
- Had close contact<sup>6</sup> with a confirmed or probable case of COVID-19 within 14 days before their illness onset OR
- Had close contact with a person with acute respiratory illness who has travelled outside of PEI within 14 days prior to their illness onset OR
- Laboratory exposure to biological material (e.g. primary clinical specimens, virus culture isolates) known to contain COVID-19.

Factors that raise the index of suspicion<sup>7</sup> should also be considered.

NOTE: All patients who are admitted to the hospital with respiratory illness should be tested for COVID-19 (beginning March 23)

March 24, 2020 4

\_

<sup>&</sup>lt;sup>5</sup> The incubation period of COVID-19 is unknown. SARS-CoV demonstrated a prolonged incubation period (median 4-5 days; range 2-10 days) compared to other human coronavirus infections (average 2 days: typical range 12 hours to 5 days). The incubation period for MERS-CoV is approximately 5 days (range 2-14 days). Allowing for variability and recall error and to establish consistency with the WHO COVID-19 case definition, exposure history based on the prior 14 days is recommended at this time.

<sup>&</sup>lt;sup>6</sup> Close contact is defined as a person who provided care for the patient, including health care workers, family members or other caregivers, or who had other similar close physical contact or who lived with or otherwise had close prolonged contact with a probable or confirmed case while the case was ill.

<sup>&</sup>lt;sup>7</sup> Other exposure scenarios not specifically mentioned here may arise and may be considered at jurisdictional discretion (e.g. history of being a patient in the same ward or facility during a nosocomial outbreak of COVID-19). All patients admitted to hospital with respiratory illness should be tested for COVID-19.

# **Reporting Requirements**

### 1. Health Practitioners

Health practitioners, shall, in accordance with the <u>Notifiable Diseases and Conditions and Communicable Diseases Regulations</u>, as part of the Prince Edward Island (PEI) <u>Public Health Act</u> (2) report all confirmed and probable cases by phone and mail, fax or electronic transfer, as soon as suspected to the Chief Public Health Officer (CPHO) (or designate) and in any case not later than 1 hour after observation, as per the <u>PEI Reporting Notifiable Diseases</u>, <u>Conditions</u>, and <u>Events Regulations</u> (3).

### 2. Laboratories

The Provincial Laboratory shall, in accordance with the PEI <u>Public Health Act</u> (2), report all positive laboratory results by phone and mail, fax or electronic transfer, as soon as the result is known, to the CPHO (or designate) and in any case not later than 1 hour after observation, as per the <u>PEI Reporting Notifiable Diseases</u>, <u>Conditions</u>, and <u>Events Regulations</u> (3).

3. Notification to the Public Health Agency of Canada (PHAC) will be reported by the Chief Public Health Officer or designate. Notification of confirmed and probable cases can be made to <a href="mailto:phac.hsfluepi.aspc@canada.ca">phac.hsfluepi.aspc@canada.ca</a> during regular hours (0800-1700hrs ET). After regular business hours please contact the Public Health Agency of Canada's Health Portfolio Operations Centre (HPOC) Watch Office by phone (1-800-545-7661) or through the single window email: <a href="mailto:phac-aspc.hpoc-cops@canada.ca">phac-aspc.hpoc-cops@canada.ca</a>.

# Etiology (4)

Coronaviruses are a large family of viruses that are common in many different species of animals, including camels, cattle, cats, and bats. Rarely, animal coronaviruses can infect people and then spread between people such as with Middle East Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome (SARS), and now with COVID-19.

Cases were initially linked to exposure to live animals at a seafood market in Wuhan City but the substantial increase in cases thereafter is due to human-to-human transmission of the virus.

The COVID-19 is an emerging respiratory pathogen with uncertain key epidemiological, clinical and virological characteristics.

# Clinical Presentation

The clinical spectrum of 2019 novel coronavirus (COVID-19) infection is still being defined. Illnesses associated with the COVID-19, are similar to several respiratory illnesses and include fever, dry cough, sore throat and headache. Most cases are considered mild to moderate with a subset experiencing more severe illness with shortness of breath and difficulty breathing. Deaths have been reported among approximately two to four per cent of detected cases in China although it is likely that the actual risk of such severe outcomes is lower given milder cases are less likely to be detected.

The complete clinical picture with regard to COVID-19 is not fully understood. Reported illnesses have ranged from infected people with little to no symptoms to severe illness and death.

# **Diagnosis**

Diagnosis is made by isolation of the COVID-19 in a nasopharyngeal swab and throat swab for PCR and sent a provincial lab for presumptive result and confirmed by the National Microbiology Laboratory (refer to Appendix A).

# **Epidemiology**

### 1. Reservoir

Early on, many of the patients in the outbreak of respiratory illness caused by COVID-19 in Wuhan, China had some link to a large seafood and live animal market, suggesting animal-to-person spread. Later, a growing number of patients reportedly did not have exposure to animal markets, indicating person-to-person spread.

### 2. Transmission

Transmission occurs person to person in symptomatic individuals via droplet.

# 3. Incubation Period

Current estimates of the incubation period range from 1 to 12.5 days with median estimates of 5-6 days.

### 4. Period of Communicability

Unknown.

# 5. Host Susceptibility

Host susceptibility remains somewhat unknown. Information indicates that risk factors for disease include host factors (chronic disease, age) and exposure factors.

# **Occurrence**

### **1. General** (6)

Novel coronavirus (COVID-19) was first detected in Wuhan City, China in December 2019. Currently hundreds of thousands of individuals have been diagnosed with the virus around the world.

# 2. Canada

Updated numbers of COVID-19 in Canada are available on the <u>Public Health Agency of Canada</u> website.

### 3. Prince Edward Island

There have been three cases of COVID-19 reported in PEI.

# **Control** (Appendix B)

# **Person Under Investigation (PUI)**

A person under investigation is defined as a person with a fever or acute respiratory illness, or pneumonia, who meets the exposure criteria and for whom a laboratory test for COVID-19 has been or is expected to be requested.

# Management of a Case/PUI

- Follow up is only done if the case/contact meets the case definition and is being investigated.
- Droplet/contact precautions are to be put in place in health care facilities until the test is confirmed and/or the case is no longer symptomatic.
- Any aerosol-generating medical procedures should be avoided in the home environment.
- Complete the <u>Interim National COVID-19 Case Report Form</u> (Appendix C).
- Precautions can be discontinued for a case 14 days after symptoms began, as long as the
  case feels well. If the case is a health care worker 2 negative swabs 24 hours apart will be
  required before resuming work.

### **Treatment of a Case**

There is no specific treatment for disease caused by a COVID-19. However, many of the symptoms can be treated and therefore treatment is based on the individual's clinical condition.

# **Management of Contacts**

Contact tracing and counselling are to be completed<sup>8</sup> for all reported cases. A close contact is defined as;

- Those who provided care for the case, including healthcare workers, family members or other caregivers, or who had other similar close physical contact without consistent and appropriate use of personal protective equipment, OR
- those who lived with or otherwise had close prolonged contact (within 2 metres) with a probable or confirmed case while the case was ill, OR
- those who have had direct contact with infectious body fluids of a probable or confirmed case (e.g., was coughed or sneezed on) while not wearing recommended personal protective equipment.

Those who are identified as a contact of a case will be instructed to <u>self-isolate</u> and monitor for symptoms for 14 days. Public Health Nursing (PHN) will be following up with the close contacts daily. If symptoms occur, testing will be arranged.

# **Self-Isolating in the Home Setting**

All people that have travelled outside Prince Edward Island are asked to <u>self-isolate</u> for 14 days upon their return regardless of symptoms. If symptomatic, a case or person under investigation (PUI) should call 811 to be screened for testing and <u>isolate</u> themselves in the home setting until advised by the Chief Public Health Office (CPHO) that isolation can be discontinued. Staying at home means:

<sup>&</sup>lt;sup>8</sup> To be completed by Public Health Nursing. March 24, 2020

- Not going out unless directed to do so (i.e. to seek medical care)
- Not going to school, work, or other public areas
- Not using public transportation (e.g. buses, taxis, etc)
- Taking short walk outside, close to home, and only if a 6 ft distance from others can be maintained.

NOTE: Exceptions will be made for individuals who are considered essential workers (e.g. health care workers, truck drivers, airline crews, essential frontline workers in the public or private sector, workers in critical sectors). Upon their return from *domestic* travel, essential workers will be:

- screened upon entry to the province
- asked to self-monitor daily for symptoms of COVID-19 if feeling well
- asked to self-isolate if experiencing symptoms of COVID-19.

# **Preventative Measures**

- Public education and communication about COVID-19.
- All travelers who have returned from outside Prince Edward Island are being asked to selfisolate for 14 days and monitor themselves and their children closely, and to call 811 if they develop any symptoms (fever, cough, or difficulty breathing).

# **Testing**

Testing will be arranged through 811.

The following criteria are being used to screen for testing from March 23-March 30:

# **Testing Group**

A person with any of the following:

- Fever (≥ 38.0 degrees Celsius)
- Cough (new or exacerbated chronic)
- Sore throat
- Runny nose
- Marked fatigue

# AND

- Traveled outside of Canada within the past 14 days,
- OR (as of March 21, 2020) traveled outside of PEI

This includes symptomatic travellers identified at a point of entry to PEI

BUT: do not test more than 2 family members per household (in order to conserve supplies).

A person with any of the following:

- Fever (≥ 38.0 degrees Celsius)
- Cough (new or exacerbated chronic)
- Sore throat
- Runny nose
- Marked fatigue

### AND

• Had close contact with a confirmed case or a person with symptoms and travel history (i.e., person under investigation)

**BUT:** do not test more than 2 family members per household (in order to conserve supplies).

A person with the following:

Fever (≥ 38.0 degrees Celsius) AND

- Cough (new or exacerbated chronic) AND with one or more of the following:
- Sore throat
- Joint pain
- Muscle aches
- Fatigue

### AND

Is admitted to hospital

A person with any respiratory symptoms

### AND

Is admitted to intensive care unit

### **BUT**

Has not been tested for COVID-19 in the past 48 hours

# Health Care Workers with any of the following:

- Fever (≥ 38.0 degrees Celsius)
- Cough (new or exacerbated chronic)

# **Infection Prevention and Control in the Community**

Follow these routine prevention measures to stay healthy:

- Wash your hands frequently with soap and water or use alcohol-based hand rub when hands are not visibly soiled.
- Cough and sneeze into your elbow or a tissue. If using a tissue, immediately place it in a waste disposal and wash your hands.
- If possible, stay home when ill with acute respiratory symptoms; if this is not possible, limit close contact with others.
- Limit touching your eyes, nose, and mouth.
- Don't share items that may have saliva on them such as drinking glasses and water bottles.
- Frequently clean surfaces like taps, doorknobs, and countertops.
- Use of masks by the general public for respiratory illnesses such as influenza and novel coronavirus have not been shown to be effective in preventing virus spread and are not recommended for prevention.

# Infection Prevention and Control in the Healthcare Facility

In the absence of effective drugs or vaccines, infection prevention and control (IPC) strategies to prevent or limit transmission of COVID-19 in healthcare facilities include:

- prompt identification
- appropriate risk assessment
- management and placement of probable and confirmed cases
- investigation and follow up of close contacts

# **Early Recognition and Source Control**

To facilitate early recognition and source control:

triage for identification and appropriate placement (source control) of patients

- masks, tissues and alcohol-based hand rubs (ABHR) should be available at entrances
- signage should be posted to instruct symptomatic patients to alert healthcare workers, thus prompting completion of a patient screening questionnaire

**IF** a person presents with symptoms of influenza-like illness:

- and within 14 days before the onset of illness, has travelled to an area outside of PEI
- and/or been in close contact with a probable or confirmed case of COVID-19

**THEN** the following actions should be taken:

- 1. Place the patient in a designated separate waiting area or space.
- 2. Encourage the patient with signs and symptoms of an acute respiratory infection to perform respiratory hygiene/cough etiquette, and provide tissues, ABHR and a waste receptacle.
- 3. Limit visitors.
- 4. Do **not** cohort with other patients (unless necessary, in which case cohort only with patients confirmed to have COVID-19 infection).

# **Application of Routine Practices and Additional Precautions**

The application of routine practices and additional precautions (RPAP) is based on a point-of-care risk assessment (PCRA). Health care workers (HCWs) should use a risk assessment approach **before** and **during** each patient interaction to evaluate the likelihood of exposure.

In addition to the consistent application of routine practices, follow contact and droplet precautions. This includes the appropriate selection and use of **all** the following personal protective equipment (PPE):

- gloves
- a long-sleeved gown
- facial protection, such as surgical/procedural mask and eye protection, face shield, or surgical/procedural mask with visor attachment
- an N95 respirator (plus eye protection) should be used when performing aerosol-generating medical procedures<sup>9</sup> (AGMPs) on a person under investigation (PUI) for COVID-19 infection.
- Hand hygiene should be performed whenever indicated, paying particular attention to during and after removal of PPE, and after leaving the patient care environment.

# **Infection Prevention and Control Guidelines**

<u>Infection Prevention and Control for Novel Coronavirus (COVID-19): Interim Guidance for Acute</u>

Healthcare Settings

March 24, 2020 10

9

<sup>&</sup>lt;sup>9</sup>Aerosol-generating medical procedures (AGMPs) are medical procedures that can generate aerosols as a result of artificial manipulation of a person's airway. AGMPs should only be performed on patients with signs and symptoms and exposure criteria consistent with COVID-19 if medically necessary.

Aerosol-generating medical procedure includes: intubation, manual ventilation, open endotracheal suctioning, cardiopulmonary resuscitation, sputum induction, nebulization, surgery, non-invasive positive pressure ventilation (CPAP, BiPAP) and autopsy.

# COVID-19

Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare

Settings

<u>Interim guidance: Public health management of cases and contacts associated with novel</u>
<a href="mailto:coronavirus disease 2019">coronavirus disease 2019 (COVID-19)</a>

Public Health Guidance for Schools (K-12) and Childcare Programs (COVID-19)

Community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada

Risk-informed decision making for mass gatherings during COVID-19 global outbreak

# References

- 1. **Public Health Agency of Canada.** Interim national case definition: Novel Coronavirus (COVID-19) [Online] Public Health Agency of Canada, February 27, 2020. [Cited: February 5, 2020.] https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/national-case-definition.html
- 2. **Prince Edward Island Legislative Council Office.** Prince Edward Island Public Health Act. [Online] December 15, 2016. [Cited: February 15, 2017.] https://www.princeedwardisland.ca/sites/default/files/legislation/p-30\_1.pdf.
- 3. **PEI Department of Health and Wellness.** It's the Law: Reporting Notifiable Diseases, Conditions, and Events. [Online] PEi Department of Health and Wellness. [Cited: March 8, 2017.] https://www.princeedwardisland.ca/sites/default/files/publications/notifiable\_diseases\_final\_feb\_12\_2 014\_1.pdf.
- 4. World Health Organization. Coronavirus [Online] World health Organization, January 2020. [Cited: February 5, 2020.] https://www.who.int/health-topics/coronavirus

# Appendix A: Novel Coronavirus (COVID-19) Testing

All people with travel and symptoms for testing will be screened through 811. Screening will take place at clinics set up in Charlottetown and Summerside. All patients admitted to the hospital for respiratory illness will be tested for COVID-19.

Test		Container	Comments
1.	Influenza A/B, RSV	Same NP swab for both tests (#1	Nasopharyngeal swab is not an AGMP <sup>10</sup>
2.	Novel Coronavirus PCR <sup>11</sup>	and #2)	Provide travel history <sup>12</sup>
3.	Mycoplasma IgM	Red-top tube	
4.	Legionella urine antigen test	Urine sample	
5.	Novel Coronavirus PCR	Throat swab	New #2 viral collection kit Provide travel history

March 24, 2020 13

-

<sup>&</sup>lt;sup>10</sup> Aerosol-generating medical procedure includes: intubation, manual ventilation, open endotracheal suctioning, cardiopulmonary resuscitation, sputum induction, nebulization, surgery, non-invasive positive pressure ventilation (CPAP, BiPAP) and autopsy.

<sup>&</sup>lt;sup>11</sup> Depending on the preliminary results and level of clinical and epidemiological concern the specimens for Novel Coronavirus will be sent to the National Microbiology laboratory within 24 hours or otherwise they will be saved for future consideration.

<sup>&</sup>lt;sup>12</sup> Include comments regarding travel history such as: "SARI- travel to X or other factors" or "Not-SARI travel to X or other factors".

# **Appendix B- Public Health Follow-up**

	Time Frame	Recommended Follow-up
Public Health management		Individuals being monitored are asked to:
for close contacts of cases		
<ul> <li>Provided care for a case i.e. Healthcare workers, family members, or others who had close physical contact without consistent and appropriate use of PPE, OR</li> <li>Lived with or otherwise had close prolonged contact (within 2 meters) with a probable or confirmed case while the case was ill, OR</li> <li>Had direct contact with infectious body fluids of a probable or confirmed case while not wearing recommended PPE.</li> </ul>	14 days from the last unprotected contact of a case	<ul> <li>Self-isolate at home for 14 days</li> <li>Follow good respiratory and hand hygiene practices</li> <li>Self-monitor for symptoms (fever, cough, shortness of breath)</li> <li>Record temperature daily and avoid the use of fever-reducing medications as much as possible.</li> <li>If symptoms develop within the 14 day monitoring schedule for testing at a testing clinic</li> </ul>
Public Health measures for	Applicable 14 days	Responsibility of Traveller
incoming travelers from outside of Prince Edward Island	following arrival to PEI.	<ul> <li>Self-isolate for 14 days following arrival to PEI and monitor for signs and symptoms (fever &gt;38.0°C, cough or shortness of breath).</li> <li>If symptoms develop within 14 days of arrival on PEI, the client is</li> </ul>
		to call 811 for screening for testing.

Appendix C

Protected B when complete

# NOVEL CORONAVIRUS (2019-nCoV) CASE REPORT FORM

SECTION 1: CASE PROTECTED INFORMATION – Local / Provincial / Territorial use only							
	DO NOT FORWARD TH	THIS SECTION TO PHAC					
CASE	Information	PROXY Information					
Last name:		Is respondent a proxy? (e.g. for deceased patient, child)					
First name:		O No Yes (complete information below)					
Usual residential address:		Last name: First name:					
City:	Province/Territory:	Relationship to case:					
Postal code:	Local Health Region:	Phone number #1:					
Phone number #1:		Phone number #2:					
Phone number #2:							
Date of Birth	(dd/mm/yyyy)						
Local Case ID:							
P/T Case ID:							
	Contact information	n for person reporting					
First and Last Names:							
Telephone #:							
Email:							

### Instructions for Completion

- Please complete as much detail as possible on this form at the time of the initial report.
- It is not expected that all fields will be completed during the initial report, but that updates will be made when information becomes available.

### Instructions to local public health authorities

- Reporting: Please report cases using normal local/provincial/territorial methods
- Travel: The Office of Quarantine Services at the Public Health Agency of Canada may be of
  assistance with requesting passenger manifests from conveyance operators, when requested to do
  so, by a local public health authority. Local public health authorities can contact the manager on-call
  1-416-MANAGER (626-2437).

# Instructions to provincial / territorial public health authorities

- Reporting of probable and confirmed cases: Data can be sent electronically to
   phac.hsfluepi.aspc@canada.ca
   or faxed to 1-613-952-4723. For fax, an email notification should be
   sent to <a href="mailto:phac.hsfluepi.aspc@canada.ca">phac.hsfluepi.aspc@canada.ca</a> (do not attach form). Provinces and territories are asked to
   report all confirmed and probable cases within 24 hours of P/T notification to PHAC.
- After regular business hours (8:00am-5:00pm ET), please contact the PHAC's Health Portfolio Operations Centre at <a href="mailto:phac-aspc.hpoc-cops@canada.ca">phac-aspc.hpoc-cops@canada.ca</a>.





2  NOVEL CORONAVIRUS (2019-nCoV) CASE REPORT FORM									
P/T Case ID:		Repo	orted Date:	(DD/MM/YYY)					
ADMINISTRATIVE INFORMATION									
O INITIAL REPORT O UPDATED REP	ORT								
Reporting Province/Territory O BC O AB O SK O MB O ON	O OC ONB	ONS OPE	ONL O YK O	INT ONU					
Contact information for P/T person reporti		<b>3</b> 110 <b>3</b> 12	<u> </u>	<u> </u>					
First Name:		Email:							
Last Name:		Telephone #:							
SURVEILLANCE CASE CLASSIFICATI		0.000							
Confirmed Probable Person	Under Investigat	ion O Does no	t meet						
CASE DETAILS									
Residency: O Canadian resident O No	n-Canadian Resid	ent, Country:							
Detected at Point of Entry? O No O Y	es, location of en	try:	Date of entry:	(dd/mm/yyyy)					
Gender: O Male O Female O Other O	Unknown	Age:	O years O r	months					
Does the case identify as Indigenous?	Yes O No C	Refused to Answ	wer O Unknown						
If yes, indicate which group:	First Nations (	Metis O Inc	it O Refused to A	Answer O Unknown					
Does the case reside on a First Nations Reserve most of the time?	Yes O No C	Refused to Answ	wer <b>O</b> Unknown						
The state of the s									
SYMPTOMS									
Symptom Onset Date:	(mm/dd	/уууу)		○ Asymptomatic					
Symptom	Yes	No	Unknown	Not asked/assessed					
Cough	0	0	0	0					
Fever (≥38°C)	0	0	0	0					
Feverish/chills (temperature not taken)	0	0	0	0					
Sore Throat	0	0	0	0					
Runny Nose	0	0	0	0					
Shortness of breath/difficulty breathing	0	0	0	0					
Nausea/Vomiting	0	0	0	0					
Headache	0	0	0	0					
General Weakness	0	0	0	0					
Pain (muscular, chest, abdominal, joint, etc.)	0	0	0	0					
Irritability/Confusion	0	0	0	0					

3   NOVEL CORONAVIRUS (2019-nCoV) CASE REPORT FORM									
Diarrhea	0		0	0	0				
Other, specify:	0		0	0	0				
PRE-EXISTING CONDITIONS and RISK FA									
Condition	Yes	No	Unknown	Not asked	Comments (specify disease)				
Cardiac disease	0	0	0	0					
Chronic neurological or neuromuscular disorder	0	0	0	0					
Diabetes	0	0	0	0					
Immunodeficiency disease/condition	0	0	0	0					
Liver Disease	0	0	0	0					
Malignancy	0	0	0	0					
Post-partum (≤6 weeks)	0	0	0	0					
Pregnancy	0	0	0	0	If yes, trimester :				
Renal Disease	0	0	0	0					
Respiratory Disease	0	0	0	0					
Other, specify:	0	0	0	0					
CLINICAL EVALUATIONS, COMPLICATIONS, and DIAGNOSES									
Clinical evaluation/diagnoses	Yes	No	Unknown	Not assessed	Comments				
					Comments				
Clinical evaluation/diagnoses	Yes	No	Unknown	assessed	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation	Yes	No O	Unknown	assessed	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status	Yes O	No O O	Unknown O	assessed O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia	Yes O O O	No O O O	Unknown O O O	assessed O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma	Yes O O O	N∘ O O O	Unknown O O O O	assessed O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress	Yes O O O O	No O O O O	Unknown O O O O O	assessed O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome	Yes	No O O O O O O	Unknown O O O O O O	assessed O O O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea	Yes	No O O O O O O	Unknown O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea  Encephalitis	Yes	No O O O O O O O	Unknown O O O O O O O O O O O O O O O O O O O	assessed O O O O O O O O O O O O O O O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea  Encephalitis  Hypotension	Yes	No O O O O O O O O	Unknown O O O O O O O O O O O O O O O O O O O	assessed O O O O O O O O O O O O O O O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea  Encephalitis  Hypotension  Pharyngeal exudate	Yes	No O O O O O O O O	Unknown	assessed O O O O O O O O O O O O O O O O O O O	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea  Encephalitis  Hypotension  Pharyngeal exudate  Renal Failure	Yes   O   O   O   O   O   O   O   O   O	No O O O O O O O O O O	Unknown	Assessed	Comments				
Clinical evaluation/diagnoses  Abnormal lung auscultation  Altered Mental Status  Clinical or radiological evidence of pneumonia  Coma  Conjunctival injection  Diagnosed with Acute Respiratory Distress Syndrome  Dyspnea  Encephalitis  Hypotension  Pharyngeal exudate  Renal Failure  Seizure	Yes   O   O   O   O   O   O   O   O   O	No O O O O O O O O O O O O O O O O O O O	Unknown	O O O O O O O O O O O O O O O O O O O	Comments				

17 March 24, 2020

# 4 | NOVEL CORONAVIRUS (2019-nCoV) CASE REPORT FORM

CLINICAL COURSE and OUTCOMES (complete if applicable)											
Cli	nical Course			Yes	No	Unknown	Admis	sion/Start Da	ate	Discharge/End Date	
Hos	spitalization			0	0	0					
Inte	ensive Care Unit (ICU	))		0	0	0					
Isol	ation (e.g. negative p	oressure)		0	0	0					
Ме	chanical ventilation			0	0	0					
	rrent Disposition: C				1227	102					
lf d	eceased: Death attri	ar in 1000 to 1000 to 10				Yes <b>O</b> No	<b>O</b> Unk		n.	2	
	Cause o	f death (as listed or	n death	certificat	e):			Date of Dea	ath:	(mm/dd/yyyy)	
EX	POSURES (add ad	lditional details in	the co	mments	secti	on as nece	ssary)				
	he 14 days prior to side of their province					OVec	ONo	<b>○</b> Pofused	to An	ower Ollpknown	
	nada?	ce/territory or resi	derice (	or outsit	ie oi	<b>O</b> Yes	<b>O</b> 140	ORefused	to An	swer OUnknown	
lf y	es, specify the follo	wing (submit addit	ional inf	ormation	on a	separate pa	ge if requ	ired):			
#	From	То	Star	t Date	En	d Date	Hotel/R	otel/Residence		Flight/Carrier Details	
	(country/city)	(country/city)	(mm	n/dd/yyyy	) (m	m/dd/yyyy)			(carrie	er name, flight #, seat #)	
1											
2											
3											
4											
	s the case in close on the confirme		If Yes,	specify (	Case II	⊃(s):	0.00	s, specify co		setting:	
cas	e in the 14 days pri						O Healthcare setting O Family Setting				
ons	set?					<u> </u>	O Work place				
	Yes O No O	Unknown				0.04550	O Unknown				
	,,,,					Ö	Other, specify:				
			Date of last contact (mm/dd/yyyy):								
100	012101 1001010 10 0 F						1000000				
	s the case in close son with fever and/		Date of	f last cor	itact (n	nm/dd/yyyy)	200	If yes, specify contact setting:			
has	been to an affected	d area** in the						O Healthcare setting O Family Setting			
14	days prior to their il	iness onset?					20000	Vork place			
0	Yes O No O	Unknown						O Unknown			
O rec O rec O criminami							0	O Other, specify:			

5   NOVEL CORONAVIRUS (2019-nCoV) CASE REPORT FORM									
live animals (not considered anim				•	O Unknown animals or at you had	If yes, where: O Home O Work O During travel O Live animal market Specify City:			
	ys prior to sympto ne case visit any h ?		O Yes	O No	O Unknown				
who had other while the case	similar close physica was ill.	l contact Of	R who lived	with or other	wise had close	hcare workers, family members or othe prolonged contact with a probable or c ase definition for the most up-to-date in	onfirmed case		
LABORATO	ORY INFORMATI	ON (micr	obiology /	virology /	serology) (c	omplete if applicable)			
Lab ID	Spe Collection Date (mm/dd/yyyy)	Type & Source		Test Method		Test Result (positive, negative, inconclusive, pending)	Test Date (mm/dd/yyyy)		
	(11111/44379997)					7 <del>17</del> 7			
1 1 <u></u> 2	ational Microbiolo			irmatory te Inconclusiv		ina			
DAY AT ATTEMPTON	. confirmation:	O Nege	ative O	(mm/dd/yy	TO PART TO THE PROPERTY	"ig			
ADDITIONA	AL DETAILS/CON	MENTS	(add as n	ecessary)					
TO BE COM	/IPLETED BY: <i>Th</i>	ne Public	Health A	gency of (	Canad <u>a</u>				
					PHAC Cas	e ID:			
Date Receiv	Date Received:				(mm/dd/yyyy)  If applicable, national outbreak ID:				

# **Appendix D: Symptom Diary for Self-Isolation**

Name:												
MRN:												
Start D	ate of Isolation:											
Day	Symptoms											
	No Symptoms	Temperature C <sup>0</sup> /F <sup>0</sup>	Sore Throat	Cough	Runny Nose	Shortness of Breath	Other Symptoms	Have you had contact with anyone outside of isolation?				
0	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			O No	O No	O No	O No						
1	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			O No	O No	O No	O No						
2	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
_			O No	o No	O No	O No						
3	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	O No	O No	○ No						
4	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	O No	○ No						
5	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	O No	○ No						
6	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	O No	○ No	○ No						
7	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	○ No	○ No						
8	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	○ No	O No						
9	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	○ No	○ No						
10	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	○ No	○ No						
11	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	O No	○ No						
12	□ None		○ Yes	o Yes	o Yes	○ Yes						
			○ No	O No	O No	○ No						
13	□ None		○ Yes	○ Yes	○ Yes	○ Yes						
			○ No	○ No	○ No	○ No						
14	□ None		○ Yes	o Yes	o Yes	○ Yes						
			○ No	○ No	○ No	○ No						
•••												